The one American analyst that has posted figures has $53 million in revenue(39 million euro), and a loss of $.22 cents/share(approximately 10.5 million euro) or -.17 euro/share.
On E-Trade, they have Crucell listed as
Strong Buy 0
Buy 2
Hold 4
Sell 2
Strong sell 3
Fidelity has about the same breakdown. This may come as a suprise to many Crucell Bulls
Last quarter, I didn't see any European estimates until the day before the CC, Yahoo europe doesn't have any Quarterly, and the yearly estimates are 8 months old.
I know there are many who don't think any of this matters, but of course it does.The good thing is there are a lot of analysts who are negative or unimpressed with Crucell(at least on paper). A good quarter, with some upside suprises would do wonders for the stock and finally turn this long term downtrend around. What would it take to impress the European Analysts? 45 million euro? 50 million euro? Up the revenues to 230 million euro or better? Improved margins? Quarterly loss of less than 10 million euro?
This was 2006 2Q release
"Crucell Announces Second Quarter 2006 Results
Leiden, The Netherlands, August 29, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, SWX: CRX) today announced its financial results for the first half-year ended June 30, 2006, based on International Financial Reporting Standards (IFRS).
Total revenues for the second quarter were €18.9 million and other operating income was €2.8 million. Net loss for the second quarter of 2006 attributable to equity holders of the parent amounted to €25.7 million. Total revenues for the six months ended June 30, 2006, were €30.6 million; other operating income amounted to €4.8 million for the first six months of 2006. Net loss for the first six months of 2006 attributable to equity holders of the parent amounted to €40.4 million."
That was revenues of 18.7 million euro and a loss of 25.7 million euro. I am hoping Crucell will handily beat revenues and net loss(a profit is too much to hope for) by a wide margin both YOY and sequentially (Q1 revenues were 35 million and loss of 18 million euro).
Managing the estimates is Oya Yavuz's biggest job. I am praying that after the upped guidance to 140 to 150 million euro(only to be thwarted by 'a holiday'?!)fiasco. Followed by the "try to placate the Street" comment by Brus at the 4Q06 CC that the 1Q07 numbers would be "very strong", only to have them lose more money in 1Q07 than in 06. I am praying that Brus and Kruimer did not compound the mistake by giving optimistic numbers in May....especially after waiting so long. I am hoping that "220 to 225 revenues and cash flow break even" are not "Gee, I think we can do that, what do you think Leon?" numbers. I hope they were cold, sober, pessimistic, 'if almost everything goes wrong' numbers. The first of the "under promise, over deliver" numbers, the first of the "grown-up" numbers. This is also assuming that Kruimer(who actually has an impressive resume), can get the expenses for Crucell in line.
BTW-July 2007 had more licenses/deals announced than any July on record, with 3. July is traditionally the worst month...substantive news wise(not counting internal news)...for Crucell. Last year we had one license and the discontinuation of Auerogen.